Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186899 | 0.89 | PTGER1 (0.52) | P2RY14PTGER1ESR2ABCB1MAP3K5 | |
| SCHEMBL3186073 | 0.89 | PTGER1 (0.45) | PTGER1ESR2MAP3K5NR1H2 | |
| SCHEMBL3176471 | 0.86 | PTGER1 (0.55) | PTGER1ESR2 | |
| SCHEMBL20367132 | 0.86 | ABCB1 (0.45) | P2RY14ESR2RAF1BRAFJAK2 | |
| SCHEMBL3184449 | 0.85 | PTGER1 (0.49) | PTGER1ESR2MAP3K5NR1H2 | |
| SCHEMBL20367121 | 0.85 | ABCB1 (0.44) | ESR2RAF1BRAFJAK2JAK3 | |
| SCHEMBL3180343 | 0.83 | PTGER1 (0.50) | P2RY14PTGER1ESR2MAP3K5NR1H2 | |
| SCHEMBL3179360 | 0.83 | PTGER1 (0.49) | PTGER1ESR2ABCB1MAP3K5NR1H2 | |
| SCHEMBL20367418 | 0.83 | KCNH2 (0.45) | P2RY14ESR2RAF1BRAFJAK2 | |
| SCHEMBL3581181 | 0.83 | PTGER1 (0.48) | PTGER1ESR2JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SCD, CYP11B2, SCD5 | P2RY14 1512/4885PTGER1 681/4885ESR2 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.